ProShare Advisors
SGMO

ProShare Advisors’s SANGAMO THERAPEUTICS INC SGMO Stock Holding History

ProShare Advisors’s Portfolio SGMO Stock Details SGMO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-19,955
Closed -$7.15K – 2105
2024
Q2 		$7.15K Sell
19,955
-6,811
-25% -$3.68K ﹤0.01% 1840
2024
Q1 		$17.9K Buy
26,766
+1,864
+7% +$1.35K ﹤0.01% 1976
2023
Q4 		$13.5K Sell
24,902
-5,416
-18% -$2.5K ﹤0.01% 1937
2023
Q3 		$18.2K Buy
30,318
+443
+1% +$474 ﹤0.01% 1791
2023
Q2 		$38.8K Buy
29,875
+2,444
+9% +$3.34K ﹤0.01% 1794
2023
Q1 		$48.3K Sell
27,431
-3,341
-11% -$9.54K ﹤0.01% 1675
2022
Q4 		$96.6K Buy
30,772
+3,511
+13% +$13.6K ﹤0.01% 1656
2022
Q3 		$134K Buy
27,261
+2,382
+10% +$12.2K ﹤0.01% 1494
2022
Q2 		$104K Sell
24,879
-12,515
-33% -$54.1K ﹤0.01% 1606
2022
Q1 		$217K Sell
37,394
-9,058
-19% -$53.9K ﹤0.01% 1840
2021
Q4 		$348K Buy
46,452
+185
+0.4% +$1.61K ﹤0.01% 1697
2021
Q3 		$417K Sell
46,267
-10,081
-18% -$99.7K ﹤0.01% 1316
2021
Q2 		$674K Buy
56,348
+5,760
+11% +$65.2K ﹤0.01% 1304
2021
Q1 		$634K Buy
50,588
+3,256
+7% +$43.9K ﹤0.01% 1291
2020
Q4 		$739K Buy
47,332
+10,496
+28% +$123K ﹤0.01% 1021
2020
Q3 		$348K Sell
36,836
-1,325
-3% -$14.3K ﹤0.01% 1097
2020
Q2 		$342K Buy
38,161
+15,490
+68% +$144K ﹤0.01% 1155
2020
Q1 		$144K Sell
22,671
-17,973
-44% -$133K ﹤0.01% 1042
2019
Q4 		$340K Sell
40,644
-3,753
-8% -$34.5K ﹤0.01% 1268
2019
Q3 		$402K Sell
44,397
-31
-0.1% -$348 ﹤0.01% 1070
2019
Q2 		$478K Sell
44,428
-1,282
-3% -$13.6K ﹤0.01% 1032
2019
Q1 		$436K Buy
45,710
+415
+0.9% +$4.24K ﹤0.01% 1071
2018
Q4 		$520K Sell
45,295
-8,571
-16% -$106K ﹤0.01% 934
2018
Q3 		$913K Sell
53,866
-2,149
-4% -$32.7K 0.01% 862
2018
Q2 		$795K Buy
56,015
+6,218
+12% +$103K 0.01% 914
2018
Q1 		$946K Sell
49,797
-8,187
-14% -$175K 0.01% 845
2017
Q4 		$951K Buy
57,984
+5,193
+10% +$77.3K 0.01% 859
2017
Q3 		$792K Buy
52,791
+9,560
+22% +$106K 0.01% 792
2017
Q2 		$380K Sell
43,231
-2,590
-6% -$16.6K ﹤0.01% 1055
2017
Q1 		$238K Sell
45,821
-11,989
-21% -$48.1K ﹤0.01% 1362
2016
Q4 		$176K Buy
57,810
+6,422
+12% +$23.4K ﹤0.01% 1625
2016
Q3 		$238K Sell
51,388
-9,583
-16% -$48.7K ﹤0.01% 1260
2016
Q2 		$353K Buy
60,971
+365
+0.6% +$2.33K ﹤0.01% 1126
2016
Q1 		$367K Sell
60,606
-5,855
-9% -$35.2K 0.01% 1120
2015
Q4 		$607K Buy
66,461
+6,537
+11% +$50.4K 0.01% 948
2015
Q3 		$338K Sell
59,924
-4,455
-7% -$36.7K ﹤0.01% 1099
2015
Q2 		$714K Sell
64,379
-4,485
-7% -$57.8K 0.01% 932
2015
Q1 		$1.08M Buy
68,864
+8,969
+15% +$139K 0.01% 810
2014
Q4 		$911K Sell
59,895
-2,219
-4% -$26.9K 0.01% 906
2014
Q3 		$670K Sell
62,114
-12,263
-16% -$160K 0.01% 1235
2014
Q2 		$1.14M Sell
74,377
-35,451
-32% -$510K 0.01% 1100
2014
Q1 		$1.99M Buy
109,828
+78,162
+247% +$1.51M 0.02% 755
2013
Q4 		$440K Sell
31,666
-21,288
-40% -$245K 0.01% 1083
2013
Q3 		$555K Buy
52,954
+8,477
+19% +$84.2K 0.01% 1371
2013
Q2 		$347K Buy
+44,477
New +$388K 0.01% 1589

Other funds holding SGMO

WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
HighTower Advisors
HighTower Advisors Chicago, Illinois $94.2B AUM 21.24% 1-Year Est. Return

ProShare Advisors's SGMO Position: Q3 2024 in Review

ProShare Advisors sold out of SANGAMO THERAPEUTICS INC (SGMO) in Q3 2024, closing a stake of 19,955 shares — an estimated $7.15K sold.

ProShare Advisors first reported a position in SGMO in Q2 2013 and held it in 45 quarters. The position peaked at $1.99M in Q1 2014. 103 funds tracked by Wall St. Rank hold SGMO as of Q3 2024.

  • ProShare Advisors reported no remaining SANGAMO THERAPEUTICS INC position as of Q3 2024 after selling out during the quarter.
  • ProShare Advisors sold 19,955 SANGAMO THERAPEUTICS INC shares in Q3 2024, an estimated $7.15K.
  • ProShare Advisors first reported a position in SANGAMO THERAPEUTICS INC in Q2 2013 and held it in 45 quarters.
  • ProShare Advisors's SANGAMO THERAPEUTICS INC position peaked at $1.99M in Q1 2014.
  • 103 funds tracked by Wall St. Rank held SANGAMO THERAPEUTICS INC as of Q3 2024.

Based on ProShare Advisors's 13F filing for Q3 2024, filed 14 Nov 2024.